Efficacy News and Research

RSS

Combination of GXR and psychostimulant safe and effective for children with ADHD

While pharmacologic agents have a demonstrated efficacy in children with Attention-deficit/hyperactivity disorder (ADHD), some children have suboptimal response to a single pharmacologic agent.

9 Jan 2012

Oxygen Biotherapeutics to commence study to determine efficacy of Dermacyte in relieving Histamine induced pruritus

Oxygen Biotherapeutics, Inc. has announced that enrollment for the company’s first dermatological study will begin later this month at St. John’s Medical College Hospital in Bangalore, India. The company received formal approval from the hospital’s Ethics Review Board in December. This study is the first of a series of trials scheduled for 2012 to explore the efficacy of Dermacyte to treat a variety of dermatological conditions, such as allergic contact dermatitis, psoriasis and acne.

9 Jan 2012

Cameron Health's PMA application for S-ICD System submitted to FDA

Cameron Health, Inc. announced today that it has submitted the Premarket Approval application to the Food and Drug Administration for the S-ICD System, the world's only completely subcutaneous implantable defibrillator.

9 Jan 2012

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

Human Genome Sciences, Inc. will today announce its priority goals for 2012 and report on progress with the commercialization of BENLYSTA (belimumab), the first approved drug for systemic lupus in 56 years, during a presentation this afternoon by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 30th Annual JPMorgan Healthcare Conference in San Francisco.

9 Jan 2012

Presidio completes PPI-668 Phase 1a study on hepatitis C

Presidio Pharmaceuticals, Inc. announced today the successful completion of a Phase 1a dose-ranging assessment of PPI-668, a potent, pan-genotypic second-generation hepatitis C virus (HCV) NS5A inhibitor, in healthy volunteers and subsequent advancement to a Phase 1b assessment of the dose-related efficacy in hepatitis C patients.

9 Jan 2012

Pfizer, SFJ to conduct axitinib Phase 3 trial in renal cell carcinoma

SFJ Pharma Ltd. II announced today that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial in Asia of Pfizer's investigational agent axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.

9 Jan 2012

JDRF, KalVista collaborate to focus on novel approach for diabetic macular edema

KalVista Pharmaceuticals and JDRF have formed a research partnership focused on a novel approach being developed by KalVista to preserve vision and slow the progression of diabetic eye disease.

9 Jan 2012

Enrollment complete in Diamyd Phase II study for type 1 diabetes

A total of 50 children aged four and older with a high risk of developing type 1 diabetes have been enrolled in a researcher-initiated Phase II study, DiAPREV-IT, with Diamyd Medical's diabetes vaccine Diamyd. The study is thus fully recruited.

9 Jan 2012

Colby's JVRS-100 enhances immunogenicity, cross-protective efficacy of H5N1 influenza vaccine

Colby Pharmaceutical Company (CPC) today announced publication of new results showing that a single dose of JVRS-100 adjuvanted H5N1 influenza vaccine enhanced-immune responses, -dose sparing, and -cross-clade influenza virus protection.

9 Jan 2012

miRagen, Silence partner to assess delivery potential of novel miRNA-based therapeutics

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces that it has signed an agreement with miRagen Therapeutics, Inc., to assess the delivery potential of Silence's proprietary DBTC delivery system with miRagen's novel microRNA-based therapeutics.

9 Jan 2012

MPIIB, QIAGEN partner to develop latent TB diagnostic test

QIAGEN N.V. and the Max Planck Institute for Infection Biology (MPIIB), Department of Immunology have announced a new collaboration to develop a molecular diagnostic test to assess the risk of an individual with latent tuberculosis (TB) developing active TB disease during their lifetime.

From QIAGEN Manchester Limited 9 Jan 2012

AICAR therapy may combat heat stroke

We've all seen the story in the news before. Whether it's the death of a physically fit high school athlete at football training camp in August, or of an elderly woman gardening in the middle of the day in July, heat stroke is a serious, life-threatening condition for which there is no treatment beyond submersion in ice water or the application of ice packs to cool the body to a normal temperature.

8 Jan 2012

Scientists develop simple, reliable test to identify biomarkers for MPS

A team of scientists, led by researchers at the University of California, San Diego School of Medicine and Zacharon Pharmaceuticals, have developed a simple, reliable test for identifying biomarkers for mucopolysaccharidoses (MPS), a group of inherited metabolic disorders that are currently diagnosed in patients only after symptoms have become serious and the damage possibly irreversible.

8 Jan 2012

Positive results from BioCryst's BCX4208 Phase 2b study on gout

BioCryst Pharmaceuticals, Inc. announced long-term results from the extension phase of its randomized Phase 2b study of BCX4208 added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone.

8 Jan 2012

Americans cutting costs by skipping prescription drugs

A Consumer Reports survey revealed that more Americans are ignoring their doctor’s advice and skipping prescription drugs or medical procedures to save money in 2011 than a year earlier.

8 Jan 2012

New U.S. patent covers key element of Xencor's Xtend half-life prolongation technology

Xencor, Inc., a company using its proprietary Protein Design Automation (PDA) platform technology to engineer next-generation antibodies, announced today that the U.S. Patent and Trademark Office has issued Xencor a broad patent covering optimized monoclonal antibody variants and their application for extending in vivo half-life of antibodies.

7 Jan 2012

Pearl Therapeutics completes two PT003 Phase 2b clinical studies on COPD

Pearl Therapeutics Inc. today announced the completion of two Phase 2b clinical studies of PT003, the Company's investigational inhaled combination bronchodilator product for the treatment of patients with moderate-to-severe COPD.

7 Jan 2012

FDA approval of raltegravir offers new weapon to treat HIV infection in children

For children and adolescents with HIV infection, the recent Food and Drug Administration (FDA) approval of the use of raltegravir, an antiretroviral drug that slows the spread of HIV infection, offers a new weapon to treat HIV infection in children.

7 Jan 2012

FDG-PET safe and accurate in detecting dementia, Alzheimer's

In a new review of imaging studies spanning more than ten years, scientists find that a method of positron emission tomography (PET) safely and accurately detects dementia, including the most common and devastating form among the elderly, Alzheimer's disease.

7 Jan 2012

Clearside Biomedical receives $4M venture capital investment

Technology developed by researchers at the Georgia Institute of Technology and Emory University for delivering drugs and other therapeutics to specific locations in the eye provides the foundation for a startup company that has received a $4 million venture capital investment.

6 Jan 2012

Efficacy News and Research

Combination of GXR and psychostimulant safe and effective for children with ADHD

Oxygen Biotherapeutics to commence study to determine efficacy of Dermacyte in relieving Histamine induced pruritus

Cameron Health's PMA application for S-ICD System submitted to FDA

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

Presidio completes PPI-668 Phase 1a study on hepatitis C

Pfizer, SFJ to conduct axitinib Phase 3 trial in renal cell carcinoma

JDRF, KalVista collaborate to focus on novel approach for diabetic macular edema

Enrollment complete in Diamyd Phase II study for type 1 diabetes

Colby's JVRS-100 enhances immunogenicity, cross-protective efficacy of H5N1 influenza vaccine

miRagen, Silence partner to assess delivery potential of novel miRNA-based therapeutics

MPIIB, QIAGEN partner to develop latent TB diagnostic test

AICAR therapy may combat heat stroke

Scientists develop simple, reliable test to identify biomarkers for MPS

Positive results from BioCryst's BCX4208 Phase 2b study on gout

Americans cutting costs by skipping prescription drugs

New U.S. patent covers key element of Xencor's Xtend half-life prolongation technology

Pearl Therapeutics completes two PT003 Phase 2b clinical studies on COPD

FDA approval of raltegravir offers new weapon to treat HIV infection in children

FDG-PET safe and accurate in detecting dementia, Alzheimer's

Clearside Biomedical receives $4M venture capital investment

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News